Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/17/2021 06/18/2021 06/21/2021 06/22/2021 06/23/2021 Date
165.22(c) 161.98(c) 163.84(c) 163.62(c) 162.63(c) Last
5 874 962 12 993 018 6 592 400 5 627 795 4 468 954 Volume
+0.48% -1.96% +1.15% -0.13% -0.61% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 92 812 M - -
Net income 2021 22 227 M - -
Net Debt 2021 314 M - -
P/E ratio 2021 19,6x
Yield 2021 2,57%
Sales 2022 97 460 M - -
Net income 2022 23 302 M - -
Net cash position 2022 7 133 M - -
P/E ratio 2022 18,0x
Yield 2022 2,71%
Capitalization 428 B 428 B -
EV / Sales 2021 4,62x
EV / Sales 2022 4,32x
Nbr of Employees 134 500
Free-Float 84,3%
More Financials
Company
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... 
Sector
Pharmaceuticals
Calendar
06/23 | 08:00amSpecial Situation
More about the company
Ratings of Johnson & Johnson
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about JOHNSON & JOHNSON
06/23JOHNSON & JOHNSONá : Medical Announces Strategic Partnership With Aussie Startup..
PU
06/23BAYERá : Submits New Drug Application To US FDA For Xarelto
MT
06/23JOHNSON & JOHNSONá : Unit Seeks US Nod For Xarelto to Treat Blood Clots in Pedia..
MT
06/23STREET COLOR : Two US House Panels Seeking Details on Emergent Relationship Betw..
MT
06/23CVRx Sets IPO at 6.25 Million Shares; Sees Pricing at $15-$17 Each
DJ
06/23JOHNSON & JOHNSONá : World Bank, African Union Partner to Buy, Distribute 400 Mi..
AQ
06/22HALOZYME THERAPEUTICSá : Says Janssen's Darzalex Gets Two Marketing Authorizatio..
MT
06/22Insulin pump Accessories Market Development, Outline, Competitive perspective..
AQ
06/22GENMAB A/Sá : Partner Janssen Secures EU Approval for Darzalex SC Combo in Rare ..
MT
06/22LEGEND BIOTECHá : Johnson & Johnson Unit to Build Manufacturing Facility in Belg..
MT
06/22JOHNSON & JOHNSONá : Economic Support Needed to Aid Post-Pandemic Recovery
AQ
06/21JOHNSON & JOHNSONá : How Johnson & Johnson Helped Us Adopt 11 Children
AQ
06/19MODERNAá : U.S. administers more than 317 mln doses of COVID-19 vaccines - CDC
RE
06/18The Week Ahead -- Barron's
DJ
06/17JOHNSON & JOHNSONá : Eying border reopening, Mexico begins J&J vaccine rollout i..
AQ
More news
News in other languages on JOHNSON & JOHNSON
06/23J&Já : sollicite deux indications pédiatriques pour Xarelto
06/23Bayer setzt auf längere Xarelto-Exklusivität in USA - Will Zulassung für Kind..
06/22CORONA-IMPFUNG FÜR SCHWANGERE : Haftungsfrage laut Experten geklärt
06/21J&Já : Ethicon présente un nouveau dispositif médical
06/21IMPFUNGEN FÜR ALLE MÖGLICH : Eine Million Buchungen in Großbritannien
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 162,63 $
Average target price 183,67 $
Spread / Average Target 12,9%
EPS Revisions
Managers and Directors
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.34%430 876
ROCHE HOLDING AG11.75%324 905
PFIZER, INC.6.09%221 725
NOVARTIS AG2.56%209 282
ABBVIE INC.6.39%202 586
ELI LILLY AND COMPANY28.58%201 295